Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Geneos Wealth Management Inc. increased its position in shares of McKesson Co. (NYSE:MCK – Free Report) by 5.6% in the 4th ...

McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Shares of McKesson Co. (NYSE:MCK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are covering the firm, Marketbeat reports. Two investment ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

The US Supreme Court on Tuesday signaled it would likely limit whether district courts must accept adjudications from the ...

In the evolving world of healthcare, robust and secure networks form the foundation of effective and innovative care support ...